



Antituberculosis Activity of Propolis

Jarosław WIDELSKI^{1*}, Joanna GOLUS², Piotr OKIŃCZYC³, Rafał SAWICKI², Grażyna GINALSKA², Konstantia GRAIKOU⁴, Zuriyadda SAKIPOVA⁵, Ioanna CHINO⁴, Krystyna SKALICKA-WOŹNIAK¹, Tomasz MROCZEK¹

¹Department of Pharmacognosy with Medicinal Plant Unit, Medical University of Lublin, Poland

²Department of Biochemistry and Biotechnology, Faculty of Pharmacy, Medical University of Lublin

³Department of Pharmacognosy, Wrocław Medical University, Wrocław, Poland

⁴Division of Pharmacognosy & Chemistry of Natural Products, Faculty of Pharmacy, National and Kapodistrian University of Athens, Greece

⁵School of Pharmacy, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan

* yarpn222@interia.pl

Received/Geliş Tarihi: 08/10/2018, Accepted/ Kabul Tarihi: 19/10/2018

*Corresponding author /Yazışılan yazar

Abstract

Tuberculosis an infectious disease caused by *Mycobacterium tuberculosis* is one of the leading causes of human morbidity and mortality. In 2013 the WHO reported one and half million of deaths and nine millions new cases of active tuberculosis caused by TB¹. The increase in the incidence of clinical tuberculosis is associated with increasing reports of new cases of multi drug resistant (MDR-TB) and extensively multidrug resistant (XDR-TB) strains¹.

Propolis (bee glue) is well known for its antibacterial and antifungal properties. More than 30 ethanol-water extracts obtained from different propolis samples were tested for antituberculosis activity.

Minimal Inhibitory Concentrations (MIC) values for the EO were established with 96-well micro plate method with AlamarBlue (Invitrogen). Reference strain of *Mycobacterium tuberculosis* H37Ra inoculum in Middlebrook 7H9 broth (Difco) was 5×10^5 cfu/ml per well, accordingly to CLSI standards. Serial twofold dilutions of propolis extracts ranged from 64 to 8 µg/ml. As the internal control of the method serial twofold dilutions of four first line antibiotics dedicated to the tuberculosis treatment: isoniazid (INH), rifampicin (RMP), ethambutol (EMB) and streptomycin (SM) were used^{2,3}.

Acknowledgments. *The work was financed from grant No 4/POLTUR-1/2016.*

References:

1. WHO (2014). Global tuberculosis report (www.who.int/tdr/news/2014/global-TB-report/en/). World Health Organization (2010). Multidrug and extensively drug resistant TB (M/ XDR-TB) Global report on surveillance and response. Geneva: World Health
- 2 Palomino, J.C., Martin, A., Camacho, A., Guerra, H., Swings, J., Portaels, F. (2002). Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy*, 46, 2720-2722
- 3 Wayne, P.A. (2011). Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard-Second Edition. CLSI document M24-A2. USA. Clinical and Laboratory Standards Institute.